Cytomegalovirus Treatment Market size was valued at $503 million in 2020, growing at a CAGR of 6.0% during the forecast period 2021-2026. Cytomegalovirus (CMV) is the most commonly transmitted herpes virus which remains dormant in the human body. It is a communicable disease and it can infect people of all ages globally. Cytomegalovirus spread through direct contact with such as saliva, blood, urine, semen, and breast milk. The symptoms of Cytomegalovirus are fatigue, fever, sweats, muscle aches, sore throat, headache and others. There many medicines are available in the market for the treatment of cytomegalovirus such as ganciclovir, valganciclovir, foscarnet, cidofovir and others. Increasing prevalence of CMV retinitis and congenital CMV infection coupled with increasing public awareness related to herpes virus infections is major factor driving the growth of the market. Moreover, growing prevalence of viral infection among AIDS patients further enhance the overall market demand for Cytomegalovirus Treatment during the aforesaid period.
In 2020, North America dominates the Cytomegalovirus Treatment Market owing to rising government funding and increasing research in the area.
Increasing innovation and development in Cytomegalovirus Treatment across the globe is driving the market growth of Cytomegalovirus Treatment.
Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the Cytomegalovirus Treatment Market report.
Adverse Effects and Risks Related to Cytomegalovirus Drugs are challenging the growth of the market.
Cytomegalovirus Treatment Market Segment Analysis- By Drugs
Based on the drugs, Cytomegalovirus Treatment Market is segmented into Ganciclovir, Valganciclovir, Foscarnet, Cidofovir, others. The Ganciclovir segment is estimated to dominate the market during the period 2021-2026. This is attributed to it is widely used as anti-viral drug to treat and prevent infections. Furthermore, Ganciclovir is most effective drug and show quick result. The Valganciclovir, segment is forecast to be the fastest-growing segment and is projected to grow at a CAGR of 5.6% during the period 2021-2026. This is mainly owing to Valganciclovir is simple and convenient and offer potential for improved patient compliance.